Pharmis Sarl Pharmaceutical Import Profile — Morocco (DGFT 2022–2026)

Name: Pharmis Sarl Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pharmis Sarl — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Pharmis Sarl

Pharmaceutical Importer · Morocco · Advanced Oncology Focus · $1.1M Total Trade · DGFT Verified

Pharmis Sarl is a pharmaceutical importer based in Morocco with a total trade value of $1.1M across 2 products in 1 therapeutic categories. Based on 24 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Pharmis Sarl sources from 7 verified Indian suppliers, with Reliance Life Sciences Private Limited accounting for 62.6% of imports.

Pharmis Sarl — Import Portfolio & Supplier Network

Pharmis Sarl import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Pharmis Sarl?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Reliance Life Sciences Private Limited	$928.7K	30	62.6%
Micro Labs Limited	$315.3K	14	21.3%
Natco Pharma Limited	$84.8K

What Formulations Does Pharmis Sarl Import?

Formulation	Value	Ships
Lenalidomide 25 MG CAPS(relidomide 25MG)1 Pack=3	$100.0K	2
Lenalidomide 10MG CAPS(relidomide 10MG)1 Pack=3	$91.0K	2
Bedaquiline 100MG tablet's 188's (239x188's)(appendix 4r, rodtep entry no:10147)(other reference(s)ci no:124011)	$75.7K	3
Relidomide 25 MG lenalidomide 25 MG	$50.0K	1
Apxia 2.5 (apixaban tablets 2.5MG) ( 2x10`s ) ( qty- 14322.000 )	$50.0K	1
Apxia 2.5 (apixaban tablets 2.5MG) ( 6x10's ) ( qty- 24080.000 )	$50.0K	1
Apxia 5 (apixaban tablets 5MG) ( 1x20's ) ( qty- 14355.000 )	$50.0K	1
Apxia 5 (apixaban tablets 5MG) ( 3x20's ) ( qty- 17388.000 )	$50.0K	1
L-asparaginase for injection 10000iu (l-asparaginase for injection 10000iu) (3262 vials	$50.0K	1
Lenalidomide 25MG CAPS (relidomide 25 MG) :1 Pack =3	$50.0K	1
Thiotepa for injection USP 100MG /vial batch no. l24f021a , mfg dt : 06/2024 , exp dt	$50.0K	1
Lenalidomide 15 MG CAPS (relidomide 15MG) (Pack 21s)	$50.0K	1
Lenalidomide 25 MG CAPS (relidomide 25MG)(1950 stp)	$50.0K	1
Human normal immunoglobulin f0r intravenous administration b.p.5 pct 100ML (immunorel 5% 100ML)	$50.0K	1
Lenalidomide 10MG CAPS (relidomide 10MG)(975 stp)	$50.0K	1

Pharmis Sarl imports 52 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lenalidomide	Advanced Oncology	$1.1M	21	0.1%	12
2	Erlotinib	Advanced Oncology	$62.5K	3	2.3%	10

Pharmis Sarl imports 2 pharmaceutical products across 1 categories into Morocco totaling $1.1M.

Pharmis Sarl — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Pharmis Sarl is a Moroccan pharmaceutical importer and wholesaler headquartered in Mohammedia, Morocco. Established in 2010, the company operates within the pharmaceutical supply chain, focusing on the importation and distribution of finished pharmaceutical formulations. With a workforce of between 50 and 100 employees and an annual turnover ranging from 50,000,000 to 100,000,000 Moroccan Dirhams, Pharmis Sarl plays a significant role in Morocco's pharmaceutical distribution network.

The company's operations are centralized at Zone Industrielle Ouest, Ain Harrouda, Route Régionale No. 322 (Ex RS111) Km 12.400, Mohammedia, Morocco. This strategic location facilitates efficient logistics and distribution across the country. Pharmis Sarl's primary activities include the wholesale distribution of pharmaceutical products, ensuring the availability of essential medications throughout Morocco.

2Distribution Network

Pharmis Sarl's distribution network is centered in Mohammedia, Morocco, with its main facility located at Zone Industrielle Ouest, Ain Harrouda, Route Régionale No. 322 (Ex RS111) Km 12.400. This location provides strategic access to major transportation routes, facilitating efficient logistics and distribution across Morocco. The company's logistics capabilities are designed to ensure timely delivery of pharmaceutical products to various regions within the country. While specific details about warehouse locations and geographic coverage beyond Morocco are not publicly available, the central location in Mohammedia suggests a focus on serving the domestic market effectively.

3Industry Role

In Morocco's pharmaceutical supply chain, Pharmis Sarl functions primarily as a wholesaler and importer. The company imports finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various stakeholders within the Moroccan healthcare system. By focusing on the importation and wholesale distribution of pharmaceutical products, Pharmis Sarl ensures the availability of essential medications across Morocco, thereby contributing to the country's healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Pharmis Sarl

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Pharmis Sarl's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.1 million USD from India across 24 shipments. The company's portfolio is heavily concentrated, with the top five products accounting for 100% of the import value. This indicates a strategic focus on specific high-demand pharmaceutical products, particularly in the advanced oncology therapeutic category.

The primary supplier, Reliance Life Sciences Private Limited, accounts for 62.6% of the total import value, followed by Micro Labs Limited at 21.3%. This concentration suggests a strong and potentially stable relationship with these suppliers. However, the reliance on a limited number of suppliers may pose risks related to supply chain disruptions or changes in supplier dynamics. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

2Supply Chain Resilience

Pharmis Sarl's supply chain resilience is influenced by its concentrated sourcing strategy. The company's dependence on a few key suppliers, notably Reliance Life Sciences Private Limited and Micro Labs Limited, could expose it to potential supply chain disruptions. While the existing supplier relationships appear stable, the lack of publicly available information on backup suppliers and formulation diversity suggests a need for strategic planning to enhance supply chain robustness.

Importing Pharmaceuticals into Morocco — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Morocco

1Regulatory Authority & Framework

In Morocco, the pharmaceutical sector is regulated by the Ministry of Health, which oversees the registration, manufacturing, distribution, and importation of pharmaceutical products. The legal framework governing these activities is primarily established by Law No. 17-04 on the Code of Medicines and Pharmacy, enacted in 2006. This law aims to protect public health by ensuring that all medicines meet the quality, safety, and efficacy standards set by the Ministry of Health.

The marketing authorization pathway for pharmaceutical products in Morocco involves several key steps:

1. Product Registration: Manufacturers or importers must submit a comprehensive dossier to the Ministry of Health, including detailed information about the product's composition, manufacturing process, clinical data, and proposed labeling.

2. Evaluation and Approval: The Ministry evaluates the submitted dossier to ensure compliance with regulatory standards. This process may involve consultations with expert committees and can take several months.

3. Issuance of Marketing Authorization: Upon successful evaluation, the Ministry grants marketing authorization, allowing the product to be legally marketed and distributed within Morocco.

This regulatory framework ensures that pharmaceutical products available in Morocco are safe, effective, and of high quality, thereby safeguarding public health.

2Import Licensing & GMP

Pharmis Sarl — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Pharmis Sarl's product strategy focuses on importing finished pharmaceutical formulations, particularly in the advanced oncology therapeutic category. This focus aligns with the growing demand for cancer treatments in Morocco, addressing a critical need within the healthcare system. The company's emphasis on high-quality products from reputable suppliers underscores its commitment to providing effective and reliable medications to the Moroccan market.

2Sourcing Profile

Pharmis Sarl's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on oncology treatments. This approach allows the company to leverage India's established pharmaceutical manufacturing capabilities and cost advantages. By focusing on finished products, Pharmis Sarl ensures that it can meet the immediate needs of the Moroccan market without the complexities associated with raw material sourcing and manufacturing.

3Market Positioning

Based on its product mix, Pharmis Sarl serves the Moroccan pharmaceutical market as a wholesaler and importer, supplying finished pharmaceutical formulations to various stakeholders, including retail pharmacies, hospitals, and government entities. The company's focus on high-demand therapeutic areas, such as oncology, positions it to meet critical healthcare needs within the country.

Frequently Asked Questions — Pharmis Sarl

What products does Pharmis Sarl import from India?

Pharmis Sarl imports 2 pharmaceutical products across 1 categories. Top imports: Lenalidomide ($1.1M), Erlotinib ($62.5K).

Who supplies pharmaceuticals to Pharmis Sarl from India?

Pharmis Sarl sources from 7 verified Indian suppliers. The primary supplier is Reliance Life Sciences Private Limited (62.6% of imports, $928.7K).

What is Pharmis Sarl's total pharmaceutical import value?

Pharmis Sarl's total pharmaceutical import value from India is $1.1M, based on 24 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Pharmis Sarl focus on?

Pharmis Sarl imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Pharmis Sarl Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.